ClinicalTrials.gg
Active, not recruitingNCT07347093Updated Jan 20, 2026

Reversal of Roux-en-Y Gastric Bypass: A Swedish National Cohort Study

An observational study in Gastric Bypass Surgery, Revisional Bariatric Surgery and Complications After Bariatric Surgery, sponsored by Vrinnevi Hospital. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Vrinnevi Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
199
Ages
18 Years and older
Sex
All
01

Study summary

Objective:

To investigates incidence, indications, symptom relief, complications, and weight outcomes after Roux-en-Y gastric bypass (RYGB) reversal.

Background:

RYGB is an effective treatment for obesity, but in rare cases may be associated with severe long-term complications requiring RYGB reversal. Evidence on incidence and outcomes is limited.

Methods:

This nationwide, multi-center, retrospective cohort study included all patients undergoing RYGB reversal in Sweden between 2007 and 2023. Data were obtained from the Scandinavian Obesity Surgery Registry (SOReg) and medical records.

02

Conditions studied

  • Gastric Bypass Surgery
  • Revisional Bariatric Surgery
  • Complications After Bariatric Surgery

Keywords

  • Roux-en-Y gastric bypass
  • Anatomical reversal
  • Indications
  • Complications
  • Outcomes
03

In context

Lead sponsor

Vrinnevi Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

National registry-based cohort

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18years) who underwent reversal of RYGB between 2007 and 2023.

Exclusion criteria

Exclusion Criteria:

  • Emergency reversal due to bowel ischemia
  • Reversal following other bariatric procedures (e.g. gastric banding)
  • Partial/functional reversals (e.g., gastro-gastric fistula or anastomosis between the Roux-limb and gastric remnant, without full reversal of RYGB)
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
199 participants (actual)
Patient registry
No

Groups and cohorts

  • Adults (≥ 18years) who underwent reversal of RYGB

    Included patients were adults (≥ 18years) who underwent reversal of RYGB between 2007 and 2023. Exclusion criteria included emergency reversal due to bowel ischemia, reversal following other bariatric procedures (e.g. gastric banding), or partial/functional reversals (e.g., gastro-gastric fistula or anastomosis between the Roux-limb and gastric remnant, without full reversal of RYGB)

06

What researchers measure

Primary outcomes

  1. Symptom relief

    Symptom relief is classified as no, partial, or complete improvement. Complete improvement was defined as full resolution of the index symptom (e.g., cessation of hypoglycemia, pain-free status without analgesics). Partial improvement denoted a clinically meaningful reduction in symptom severity or frequency that did not meet criteria for complete resolution. No improvement indicated persistent symptoms.

    Time frame: Through study completion, an average of 2 years.

Secondary outcomes

  1. Indications for surgery

    Indications are categorized as abdominal pain, malnutrition, gastrointestinal symptoms, post-bariatric hypoglycemia, and psychological distress, and reported as number (frequencies).

    Time frame: Through study completion, an average of 2 years.

  2. Weight outcome after surgery

    Weigth \[in kilograms\] will be reported at baseline (before surgery), at one year follow-up, and two-year follow-up.

    Time frame: Through study completion, an average of 2 years.

  3. Complications

    Complications after surgery are registered as any complication and major complication (defined as Clavien-Dindo classification \>=3b), presented as number (frequencies).

    Time frame: At 30-day follow-up and one-year follow-up after surgery.

  4. Height

    Height (in meters) will be used to report BMI (in kg/m2).

    Time frame: Through study completion, an average of 2 years

  5. BMI

    Weight (in kilograms) and height (in meters) will be combined to report BMI (in kg/m2) at baseline (before surgery), at one year follow-up, andat two-year follow-up.

    Time frame: Through study completion, an average of 2 years.

Other outcomes

  1. Surgical technique

    * Surgical approach (laparoscopic or open procedure) * Handling of the Roux limb (resection or reconnection) * Jejuno-jejunostomy technique (stapled/handsewn) * Pyloroplasty/pyloromyotomy (yes/no) * Gastro-gastrostomy technique (stapled/handsewn) * Blood loss during surgery (ml) * Operation time (minutes) -all data presented as number (frequencies)

    Time frame: Perioperative/periprocedural

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Since reversal of RYGB is a rare procedure the risk of identifying individual patients is considerable even if data are pseudonymized.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 16, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
May 31, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347093
Lead sponsor
Vrinnevi Hospital
Responsible party
Ellen Andersson (Associate professor, senior consultant, Vrinnevi Hospital) — Principal investigator
First posted
Jan 16, 2026
Start date
Nov 1, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
May 31, 2026 (estimated)
Last update
Jan 20, 2026

Study contacts

Ellen A Andersson, MD
principal investigator · Department of Surgery, Vrinnevi Hospital, Norrköping, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion